List view / Grid view
Scientists have decoded the 3D structure of a key enzyme linked to Alzheimer's disease. This breakthrough opens up new possibilities for targeted drug development and better treatment options.
A University of Sydney study reveals how DNA origami can build programmable nanostructures, with promising applications in targeted drug delivery and nanorobotics.
Five distinct CRC prognostic subtypes were identified, which could revolutionise the way CRC is diagnosed and treated.
The study’s results indicate that spatial sequencing of mixed-type breast cancers could inform personalised treatment.
17 July 2024 | By Eurofins Discovery
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
Researchers have obtained images with a previously unseen level of detail, demonstrating how RNA polymerase opens the transcription bubble.
HIV-Tocky, a new viral reporter system, uncovers the molecular mechanisms of provirus silencing and expression.
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
In this episode, we explore our understanding of DNA and its implications for health outcomes. Additionally, we discuss the transition from DNA sequencing to actionable insights in medicine, contrasting genetics-driven drug discovery with traditional methods. Finally, we examine the evolving landscape of genetic technology and its potential impact on the…
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches.
Researchers discovered that smooth muscle cells can change into cancer-like cell types and worsen atherosclerosis.
Researchers discover that fusion proteins and a gene regulatory protein complex interact through disordered domains.
Researchers find that the RAD51 protein prevents genomic duplications that could arise from reactivated origins.
Researchers discover a mechanism that could be exploited for targeting other viruses that build capsids to hide from host defences.
Introducing Dr Beate Mueller-Tiemann, whose journey spans continents and disciplines, with a passion for biochemistry and molecular biology since her high school days. From elucidating pivotal proteins in cancer to monoclonal antibody discovery, Dr Mueller-Tiemann's contributions have not only transformed our understanding of diseases but have also fuelled research in…
